Register
Login
Home
Products
Doctor
Product Information
About Dry Eye Disease
TearLab in your Practice
Using TearLab in Research
Training Videos
Regulatory
United States
FDA
CLIA
Certification / Laboratory Director
Outside United States
FAQ
Articles & Publications
Professional Links
Marketing Resource Center
The Learning Center
Patient
Dry Eye Disease 101
Dry Eye Disease Overview
Symptoms of Dry Eye
Causes of Dry Eye
Possible Long Term Effects
Treatment
Dry Eye Diagnosis
Product Information
See the TearLab Test
Dry Eye Questionnaire
Track Your Progress
Articles & Publications
Patient Links
FAQ
Distributor
Find A United States Sales Representative
Find A Worldwide Distributor
Become a Distributor
Distributor Secure Section
Investor
Reimbursement
United States
Reimbursement Support Center
What code do I use?
Sample Coding Form
CMS Reimbursement
Private Payer Reimbursement
Related Diagnostic Codes
Common Issues for Claim Denial
Resources
Outside United States
Support
ISO Certification
Warranty Information
Troubleshooting Guide
Technical Library
Manuals
User Manuals
Quick Reference Guides
Test Card
Pen
Electronic Check Card
Osmolarity Control Solutions IFU
Certifications
About
Company
Management Team
Board of Directors
Senior Clinical Advisors
Scientific Advisors
Clinical Advisory Board
Corporate Governance
Careers
Investor Relations
Shareholder Information
Press Releases
Archive
Stock Quotes & Charts
SEC & SEDAR Filings
Annual Reports & Form 10-K
Webcasts
Contact Information
Order
Contact
Contact Us
Find a Doctor
Find A United States Sales Representative
Find A Worldwide Distributor
Become a Distributor
Investor Relations
Back
Home
Investor Relations
Press Releases
Archive
Shareholder Information
Press Releases
Archive
Stock Quotes & Charts
SEC & SEDAR Filings
Annual Reports & Form 10-K
Webcasts
Contact Information
Press Release Archive
TearLab Corporation Announces Change in Company Leadership
Jun 29, 2009
Positive Data From the TearLab™ Osmolarity System 510K Submission Presented Today at the American Academy of Ophthalmology (AAO) and European Society of Ophthalmology (SOE) 2008 Joint Meeting
Nov 11, 2008
OccuLogix Reports Q3-08 Financial Results
Nov 10, 2008
OccuLogix Regains Compliance With NASDAQ Continued Listing Requirements
Oct 30, 2008
OccuLogix Submits 510(k) Premarket Notification for the Tearlab™ Osmolarity System
Oct 29, 2008
OccuLogix Provides Progress Update on the Commercial Development of Its TearLab™ Osmolarity System
Oct 15, 2008
OccuLogix Effects Reverse Stock Split
Oct 07, 2008
OccuLogix Announces Closing of Transactions
Oct 06, 2008
OccuLogix Announces Stockholder Approval of Proposals
Sep 30, 2008
OccuLogix Announces Stay of NASDAQ Panel Decision
Sep 16, 2008
OccuLogix Announces Receipt of NASDAQ Panel Decision
Sep 08, 2008
OccuLogix Announces Date of Annual and Special Meeting of Stockholders
Aug 29, 2008
OccuLogix Reports Q2-08 Financial Results
Aug 06, 2008
OccuLogix's Request to Transfer to NASDAQ Capital Market Approved
Jul 29, 2008
OccuLogix Secures Additional Bridge Loan
Jul 28, 2008
OccuLogix, Inc. Files Restatements of Financial Statements
Jul 21, 2008
OccuLogix, Inc. Announces Restatements of Financial Statements Relating to Consolidation of OcuSense, Inc.
Jun 18, 2008
OccuLogix Announces U.S.$5,076,500 Private Placement of Common Stock
May 20, 2008
OccuLogix Reports Q1-08 Financial Results
May 07, 2008
OccuLogix Secures Additional Bridge Loan
May 05, 2008
OccuLogix Enters Into Definitive Merger Agreement to Acquire 100% of OcuSense
Apr 22, 2008
OccuLogix' POC Diagnostics Subsidiary, OcuSense, Achieves ISO 13485:2003 Certification
Apr 08, 2008
OccuLogix' POC Diagnostics Subsidiary Achieves Final TearLab™ Osmolarity System Development Milestone and Progresses to Manufacturing Stage
Apr 04, 2008
OccuLogix Receives Going Concern Qualification
Mar 24, 2008
OccuLogix Receives Nasdaq Delisting Letter and Confirms Intention to Appeal
Mar 20, 2008
OccuLogix Reports 2007 Financial Results
Mar 17, 2008
OccuLogix Secures $3 Million Bridge Loan
Feb 19, 2008
OccuLogix Receives Letter From Nasdaq Regarding Non-Compliance With Minimum Market Value of Publicly Held Shares Rule
Feb 05, 2008
OccuLogix Provides Update
Jan 09, 2008
OccuLogix Sells SOLX Subsidiary
Dec 20, 2007
OccuLogix Reports Q3-07 Financial Results
Nov 09, 2007
OccuLogix Provides Update on Expected Timing of Q3-07 Results Release
Nov 07, 2007
OccuLogix Suspends RHEO(TM) System Clinical Development Program
Nov 01, 2007
OccuLogix to Release Q3-07 Financial Results on November 7-Conference Call to Follow
Oct 25, 2007
OccuLogix Board Authorizes Exploration of Strategic Alternatives to Enhance Shareholder Value
Oct 09, 2007
OccuLogix Receives Letter from Nasdaq Regarding Noncompliance with Minimum Bid Price Rule
Sep 19, 2007
OccuLogix Reports Q2-07 Financial Results
Aug 08, 2007
OccuLogix to Release Q2-07 Financial Results on August 8-Conference Call to Follow
Jul 25, 2007
OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
Jul 03, 2007
OccuLogix Reports Q1-07 Financial Results
May 09, 2007
OccuLogix to Release Q1-07 Financial Results on May 9-Conference Call to Follow
Apr 25, 2007
OccuLogix Receives Going Concern Qualification
Mar 15, 2007
OccuLogix Reports Fourth Quarter and Full-Year 2006 Financial Results
Mar 06, 2007
OccuLogix to Present at Cowen and Company 27th Annual Health Care Conference
Feb 27, 2007
OccuLogix to Announce Fourth Quarter and Full-Year 2006 Financial Results on March 6-Conference Call to Follow
Feb 20, 2007
OccuLogix Announces US$10 Million Private Placement of Common Stock to Institutional Investors
Feb 01, 2007
OccuLogix's RHEO-AMD Trial Protocol Cleared by the FDA
Jan 29, 2007
OccuLogix Further Expands Focus on Age-Related Eye Diseases Through its Equity Investment in OcuSense
Nov 30, 2006
OccuLogix Reports Q3-06 Financial Results
Nov 01, 2006
OccuLogix to Present at CIBC World Markets 17th Annual Healthcare Conference
Oct 24, 2006
OccuLogix and Asahi Kasei Medical Sign Rheofilter'TM' SR Agreement
Oct 23, 2006
OccuLogix to Release Q3-06 Financial Results on November 1-Conference Call to Follow
Oct 17, 2006
OccuLogix Announces Stock Ticker Symbol Changes
Sep 01, 2006
OccuLogix Completes Acquisition of SOLX
Sep 01, 2006
OccuLogix Reports Q2-06 Financial Results
Aug 03, 2006
OccuLogix Enters Into Definitive Agreement to Acquire SOLX
Aug 01, 2006
OccuLogix to Release Q2-06 Financial Results on August 3-Conference Call to Follow
Jul 24, 2006
OccuLogix Terminates Negotiations with Sowood
Jun 30, 2006
OccuLogix Enters Into Letter of Intent for Proposed Private Sale of Zero-Coupon Convertible Notes
Jun 14, 2006
OccuLogix Reports On Meeting With FDA
Jun 12, 2006
OccuLogix Reports Q1-06 Financial Results
May 08, 2006
OccuLogix to Release Q1-06 Financial Results on May 8-Conference Call to Follow
May 01, 2006
OccuLogix Expands Focus on Age-Related Eye Diseases
Apr 04, 2006
OccuLogix Reports Positive MIRA-1 Analysis Results
Mar 09, 2006
OccuLogix Reports Fourth Quarter and Full-Year 2005 Financial Results
Mar 09, 2006
OccuLogix to Release Fourth Quarter & Full Year 2005 Financial Results and Provide a MIRA-1 Analysis Update on March 9-Conference Call to Follow
Mar 01, 2006
OccuLogix Provides MIRA-1 Update
Feb 03, 2006
OccuLogix Announces Acceleration of Stock Options Vesting
Dec 14, 2005
OccuLogix Establishes Scientific Advisory Board
Dec 13, 2005
All 12-Month Follow-up Visits Completed in OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration
Nov 17, 2005
OccuLogix Achieves ISO 13485:2003 Certification
Nov 09, 2005
OccuLogix Reports Q3-05 Financial Results
Nov 07, 2005
Time Change Notice-OccuLogix Presentation at SG Cowen 6th Annual Global Healthcare Conference
Nov 04, 2005
OccuLogix Announces Upcoming Investment Community Events
Oct 20, 2005
OccuLogix, Inc.: Options Grant to Steve Parks, Vice President, Sales
Oct 14, 2005
FDA and OccuLogix Agree on Statistical Analysis & Filing Plans
Oct 11, 2005
OccuLogix, Inc.: Accomplished Industry Veteran, Steve Parks, Joins OccuLogix as Vice President of Sales
Oct 05, 2005
OccuLogix to Present at ThinkEquity Partners 3rd Annual Growth Conference
Aug 30, 2005
OccuLogix Reports Q2-05 Financial Results
Aug 04, 2005
OccuLogix to Release Q2-05 Financial Results on August 4-Conference Call to Follow
Jul 21, 2005
OccuLogix, Inc.: Positive PERC Data Presented at ASRS 2005 Annual Meeting
Jul 18, 2005
OccuLogix, Inc.: RHEO'TM' Mechanism of Action Article Published in the Canadian Journal of Ophthalmology
Jun 07, 2005
OccuLogix Appoints Veteran Life Sciences Financial Executive, John Y. Caloz, as CFO
May 19, 2005
OccuLogix Reports Q1-05 Financial Results
May 05, 2005
OccuLogix, Inc.: Positive RheoNet Registry Clinical Data Presented at ARVO 2005
May 03, 2005
OccuLogix Appoints Adrienne L. Graves, Ph.D. to Its Board of Directors
May 02, 2005
OccuLogix to Release Q1-05 Financial Results on May 5-Conference Call to Follow
Apr 21, 2005
OccuLogix Appoints Gilbert S. Omenn, M.D., Ph.D. to Its Board of Directors
Apr 18, 2005
OccuLogix to Present at the Scotia Capital Pharmaceutical & Biotechnology Conference
Apr 12, 2005
Time Change Notice-OccuLogix Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Apr 01, 2005
OccuLogix Re-Acquires its Intellectual Property Rights to Non-Ophthalmic Indications for RHEO in North America
Mar 29, 2005
OccuLogix to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Mar 28, 2005
OccuLogix to Present at Smith Barney Citigroup 2005 Healthcare Conference
Mar 11, 2005
OccuLogix Reports Fourth Quarter and Year End 2004 Financial Results
Mar 07, 2005
OccuLogix to Present at SG Cowen & Co. 25th Annual Health Care Conference
Mar 01, 2005
OccuLogix Receives FDA Clearance to Initiate MIRA-1 Crossover Studies
Feb 28, 2005
OccuLogix to Release Q4 and Full-year 2004 Financial Results on March 7, 2005-Conference Call to Follow
Feb 22, 2005
OccuLogix to Present at Smith Barney Citigroup 2005 Small & Mid-Cap Conference
Feb 03, 2005
OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration Exceeds Patient Recruitment Goal
Jan 03, 2005
OccuLogix, Inc. Closes its Initial Public Offering of 8,400,000 Shares of Common Stock
Dec 16, 2004
OccuLogix, Inc. Prices Initial Public Offering of its Common Stock at US$12 Per Share
Dec 09, 2004
TLC Vision Corporation: Occulogix, Inc. Files Preliminary Prospectus in Canada in Connection With The Initial Public Offering of its Common Stock
Aug 31, 2004
OccuLogix, Inc. Files Registration Statement With The U.S. Securities And Exchange Commission For The Initial Public Offering Of Common Stock
Aug 13, 2004
TLC Vision Corporation And OccuLogix, Inc. Announce OccuLogix, Inc.'s Proposed Initial Public Offering Of Its Common Stock
Aug 09, 2004
Follow us
Powered by Innovasium